Breast cancer treatment resistance linked to signaling pathwaySeptember 23, 2008PHILADELPHIA -- Activation of the Src signaling pathway may cause resistance to standard medical treatment in some patients with breast cancer, and inhibition of this pathway holds the potential to overcome that resistance, according to data presented here at the American Association for Cancer Research Molecular Diagnostics in Cancer Therapeutic Development meeting. "If this finding is confirmed in clinical trials, which are currently being designed, then inhibiting Src signaling while giving standard of care medical treatment might allow us to overcome some aspects of drug resistance in the clinic," said Christina M. Coughlin, M.D., Ph.D., medical director and global medical monitor at Wyeth Pharmaceuticals, who lead this research in Wyeth's Department of Discovery Translational Medicine. The identification of genetically altered pathways in human tumors, and their subsequent inhibition, has become a major treatment strategy in many cancers. Herceptin, also known as trastuzumab, targeted HER2 in patients with breast cancer and was one of the first therapies to use this approach. Now, many newer cancer drugs have labeling to help oncologists identify patients based on expression of the drug target. Some known pathways have no genetic events to help identify patients. Src is one of the oldest known oncogenes, active in many human cancers but with no known predisposing genetic event. Coughlin said researchers suspected that some part of its pathway, either downstream or upstream, may be driving tumor development and treatment resistance. Understanding which parts of the pathway to measure in human tumors is key to developing molecular diagnostics that could eventually allow oncologists to select appropriate patients for a Src inhibitor in the clinic. For the current study, Coughlin and colleagues performed quantitative tissue microarray sampling among almost 650 patient samples to analyze for the expression of markers of the Src pathway. According to Coughlin, the patients represented the entire spectrum of breast cancer, and researchers identified subsets of patients with high Src activation who expressed low levels of estrogen receptor, progesterone receptor and HER2, also known as triple negative breast cancer, as well as subsets expressing the estrogen or progesterone receptors. These patient sets had lower overall survival associated with expression of Src signaling pathway biomarkers, which suggests that Src pathway activation may have played a role in treatment resistance. "This gives us all the pieces to the puzzle. This type of cancer signaling pathway study holds the potential to help determine who the appropriate patients are for the newer targeted drugs that we have to treat breast cancer in the absence of genetic signals for a given drug target. We can then translate that information into molecular diagnostics that can be applied within the clinical trials," Coughlin said. American Association for Cancer Research |
|||||||||||||||||||||
| Related Signaling Pathway Current Events and Signaling Pathway News Articles Researchers use drug-radiation combo to eradicate lung cancer Researchers at UT Southwestern Medical Center have eliminated non-small cell lung (NSCL) cancer in mice by using an investigative drug called BEZ235 in combination with low-dose radiation. That '4 hour erection': new discovery may help prevent a complication of priapism For men coping with painful erections lasting for long periods of time, or priapism, new research published online in The FASEB Journal (http://www.fasebj.org) offers hope. Master regulator found for regenerating nerve fibers in live animals Researchers at Children's Hospital Boston report that an enzyme known as Mst3b, previously identified in their lab, is essential for regenerating damaged axons (nerve fibers) in a live animal model, in both the peripheral and central nervous systems. The food-energy cellular connection revealed Our body's activity levels fall and rise to the beat of our internal drums-the 24-hour cycles that govern fundamental physiological functions, from sleeping and feeding patterns to the energy available to our cells. Loss of tumor supressor gene essential to transforming benign nerve tumors into cancers Researchers at UCLA's Jonsson Comprehensive Cancer Center showed for the first time that the loss or decreased expression of the tumor suppressor gene PTEN plays a central role in the malignant transformation of benign nerve tumors called neurofibromas into a malignant and extremely deadly form of sarcoma. KEAP1 Keeps major cancer-promoting protein at bay A tumor-suppressing protein snatches up an important cancer-promoting enzyme and tags it with molecules that condemn it to destruction, a research team led by scientists at The University of Texas M. D. Anderson Cancer Center reports this week in the journal Molecular Cell. Experimental drug lets B cells live and lymphoma cells die An investigative drug deprived non-Hodgkin lymphoma cells of their ability to survive too long and multiply too fast, according to an early study published recently in the journal Experimental Hematology. Cancer Predisposition From Gene Variant Shows Strong Gender Bias Cancer predisposition resulting from the presence of a specific gene variant shows a strong gender bias, researchers at the University of Cincinnati (UC) have demonstrated. Plants on steroids: Key missing link discovered Researchers at the Carnegie Institution's Department of Plant Biology have discovered a key missing link in the so-called signaling pathway for plant steroid hormones (brassinosteroids). Scottsdale Healthcare-TGen clinical trial results signal advances against skin cancer Analyses of clinical trial results published today in the New England Journal of Medicine (NEJM) shows a potential new investigational therapy for advanced and metastatic basal cell skin cancer. More Signaling Pathway Current Events and Signaling Pathway News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||